Company: KVACU
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0001213900-25-021314
Chunk: 3

Company: Keen Vision Acquisition Corp.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1
Chunk 3
---
 Unit consists of one ordinary share (“Ordinary
Share”) and one redeemable warrant (“Warrant”). The Units were sold at an offering price of $10.00 per Unit, generating
gross proceeds of $149,500,000.

Simultaneously with the closing
of the IPO, the Company consummated the Private Placement with KVC Sponsor LLC (the “Sponsor”) of 678,575 units (the “Private
Units”) at a price of $1.00 per Private Unit, generating total proceeds of $6,785,750. The Private Units are identical to the Units
sold in the IPO. The Sponsor agreed not to transfer, assign or sell any of the Private Units or underlying securities (except in limited
circumstances, as described in the Registration Statement) until the completion of the Company’s initial business combination. The
holder of the Private Units was granted certain demand and piggyback registration rights in connection with the purchase of the Private
Units.

On July 27, 2023, a total
of $151,368,750 of the net proceeds from the IPO and the Private Placement were deposited in a Trust Account established for the benefit
of the Company’s public shareholders.

The Private Units were issued
pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, as the transaction did not involve a public offering.

Business Strategy

Our business strategy is to
leverage our management team’s expertise, networks and operational experience to identify and complete our initial business combination
with a growth-focused, leading company in biotech, consumer goods, or agriculture, evaluated based on ESG imperatives. We will seek a
company with characteristics that will complement and benefit from our management team’s skills to deliver shareholder value.

Our sponsors, management team
and directors have a complementary combination of experience and skills that will greatly enhance the likelihood for success in consummating
our initial business combination, including:

    ●
    extensive global networks with management teams of public and private companies, investment bankers, PE sponsors, other public investors, entrepreneurs, industry investors, auditors, legal offices and companies;

    ●
    decades of experience in the biotech, agriculture, consumer goods, and related sectors as well as familiarity with business practices around the world, especially in the Americas and in Asia;

    ●
    track record of serial entrepreneurship and growth acceleration;

3

    ●
    expertise in a wide range of functions, including operations,